BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Furthermore, it increased subG1 the most in cells subjected to 0.5 μM Imatinib (Fig. 2D), suggesting that miR-342-5p can affect CML cell survival and tolerance to imatinib by inhibiting the expression of BCR-ABL.